Vimarsana
Biggest News Aggregation in the World

Page 28 - Practice Guidelines News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Practice Guidelines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Practice Guidelines Today - Breaking & Trending Today

Outcomes4Me Announces Investments to Accelerate Life-Saving Treatments for Cancer Patients - Vimarsana News

Outcomes4Me Announces Investments to Accelerate Life-Saving Treatments for Cancer Patients

/PRNewswire/ -- Outcomes4Me Inc., the developer of the first direct-to-patient, personalized and evidence-based cancer navigation platform, announced today it...

Latest Blood Cancer Treatment Updates Presented at Annual NCCN Event During Blood Cancer Awareness Month - Vimarsana News

Latest Blood Cancer Treatment Updates Presented at Annual NCCN Event During Blood Cancer Awareness Month

/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) 2023 Annual Congress: Hematologic Malignancies™ returns to San Francisco this week, for the...

Latest blood cancer treatment updates present - Vimarsana News

Latest blood cancer treatment updates present

NCCN 2023 Annual Congress: Hematologic Malignancies features expert perspectives on developments in blood cancer treatment, including NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Updates, CAR T-Cell therapy, BTK Inhibitors, Bispecific T-Cell Engagers, and More. The live event is taking place September 22-23, 2023, at the Hilton San Francisco Union Square. For full details and to register, visit NCCN.org/hem.

Clinical Overview: Fecal Microbiota Transplantation vs Live Biotherapeutic Products for Management of Recurrent C Difficile Infection - Vimarsana News

Clinical Overview: Fecal Microbiota Transplantation vs Live Biotherapeutic Products for Management of Recurrent C Difficile Infection

Although antibiotics are the standard-of-care treatment for Clostridioides difficile infection, they can cause further microbiota changes that predispose patients to recurrence.

Novartis : Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer -September 14, 2023 at 01:26 pm EDT - Vimarsana News

Novartis : Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer -September 14, 2023 at 01:26 pm EDT

Breast Cancer. NCCN Guidelines. Published March 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf/ Accessed August 2023. European Society...